Scott Moomaw Sells 9,539 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 9,539 shares of the stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $682,133.89. Following the sale, the insider owned 182,485 shares of the company’s stock, valued at approximately $13,049,502.35. This represents a 4.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Up 7.4%

Shares of NASDAQ LQDA traded up $5.28 during trading hours on Tuesday, hitting $76.49. The company’s stock had a trading volume of 1,153,916 shares, compared to its average volume of 2,219,263. Liquidia Corporation has a 12 month low of $14.04 and a 12 month high of $82.96. The stock has a market cap of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The business has a 50-day simple moving average of $66.37 and a 200-day simple moving average of $47.52.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. On average, analysts anticipate that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LQDA has been the topic of a number of research reports. BTIG Research lifted their target price on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. HC Wainwright increased their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC lifted its stake in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Liquidia during the third quarter valued at approximately $38,887,000. MPM Bioimpact LLC raised its holdings in Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC purchased a new position in Liquidia in the 3rd quarter worth approximately $12,571,000. Finally, Bank of America Corp DE lifted its position in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).